New Podcast Episode by PharmaSources!

[Pharma Sources]

View this E-mail (https://info.cphi-chinaedm.com/x/?S7Y1Mf2fa2tsYGJu9j.H1tTAwsDyf5GthaGxsZkBAAA59)  (https://info.cphi-chinaedm.com/x/?S7Y1Mf2fa2tsYGJu9j.H1tTAwsDyf5GthaGxsZkBAAA59)online

 (https://www.pharmasources.com/pharmavibe/?utm_source=EDM&utm_medium=online&am p;utm_campaign=enedmpodcast0504)
WELCOME TO
PharmaVibe
Podcast hosted by PharmaSources

Listen and sense the heartbeat of the industry through news stories, key conferences, and in-depth interviews encompassing an array of specialties, sectors, and areas.
Subscribe Now (https://www.pharmasources.com/pharmavibe/?utm_source=EDM&utm_medium=online&am p;utm_campaign=enedmpodcast0504)
 (https://www.pharmasources.com/pharmavibe/?utm_source=EDM&utm_medium=online&am p;utm_campaign=enedmpodcast0504)
Latest Release

 

EPISODE 14 | 11 MIN | 04 May 2022
#Drug Review   #R&D   #Business
Weekly Pharma News Review 
(Apr.24-May.1)

The Virtual Expo Connect 2022 is in full swing this week. Cameron Bardliving, director of operations, and Peter Shapiro, senior director appeared in the VEC webinar and conducted in-depth sharing and discussion focusing on new cell and gene therapies.

AstraZeneca and Daiichi Sankyo’s HER2-directed antibody-drug conjugate Enhertu has been granted Breakthrough Therapy Designation for patients with HER2-low metastatic breast cancer in the U.S. While in China, its marketing application for the treatment of patients with HER2-positive unresectable or metastatic breast cancer treated with one or more prior anti-HER2-based regimens was proposed to be included in the updated publicity list of priority review. 
Play (https://www.pharmasources.com/pharmavibe/detail/14.html/?utm_source=EDM&utm_medium=online&am p;utm_campaign=enedmpodcast0504)

 

Featured Episode

EPISODE 13 | 12 MIN | 27 Apr. 2022#Drug Review  #R&D  #Business
Weekly News Review (Apr.18-Apr.24)
Play (https://www.pharmasources.com/pharmavibe/detail/13.html/?utm_source=EDM&utm_medium=online&am p;utm_campaign=enedmpodcast0504)

EPISODE 12 | 14 MIN | 20 Apr. 2022#Drug Review  #R&D  #Personnel Changes
Weekly News Review (Apr.11-Apr.17)
Play (https://www.pharmasources.com/pharmavibe/detail/12.html/?utm_source=EDM&utm_medium=online&am p;utm_campaign=enedmpodcast0504)

 (https://www.pharmasources.com/vec2022?utm_source=EDM&utm_medium=online&am p;utm_campaign=enedmpodcast0504)Virtual Expo Connect (VEC) is back and registration for the event is now alive! This year the 2 month-event returns with more opportunities for you to connect, source, learn and grow pharma business online. Get registered to enjoy your VEC journey!
Register for free (https://www.pharmasources.com/vec2022/register?utm_source=EDM&utm_medium=online&am p;utm_campaign=enedmpodcast0504)

 (https://efile.imsinoexpo.com/efile/CPhI/Yingqi/PharmaSources%20Sponsorship%20Package%20final.pdf?utm_source=EDM&utm_medium=online&am%20p;utm_campaign=enedmpodcast0504)  
----------------------------------------------------------------------------------

 (https://www.facebook.com/Pharmasources/?utm_source=EDM&utm_medium=online&am%20p;utm_campaign=enedmpodcast0504) (https://twitter.com/Pharmachina365/?utm_source=EDM&utm_medium=online&am%20p;utm_campaign=enedmpodcast0504) (https://www.linkedin.cn/company/pharmasources?utm_source=EDM&utm_medium=online&am%20p;utm_campaign=enedmpodcast0504)
Customer Service
+86-13621645194
PharmaSources at imsinoexpo.com (mailto:PharmaSources at imsinoexpo.com)

Telegram

WhatsApp

If you no longer wish to receive our e-mail updates,
please go here to unsubscribe. (https://info.cphi-chinaedm.com/x/plugin/?pName=unsubscribe&MIDRID=S7Y1Mf2fa2tsYGJu9j.H1tTAwsDyf5GthaGxsZkBAAA59&Z=1691495543)
   
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.nottingham.ac.uk/pipermail/affymetrix-arabidopsis/attachments/20220504/e8ee39f3/attachment-0001.html>